Literature DB >> 32991231

Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.

Ping-Han Huang1, Hsiao-Han Tsai2,3, Bo-Hung Liao2, Yi-Ling Lin2, Jia-Tsrong Jan4, Mi-Hua Tao2, Yu-Chi Chou5, Che-Ming Jack Hu2, Hui-Wen Chen1.   

Abstract

A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

Entities:  

Keywords:  SARS-CoV-2; neutralizing antibodies; receptor-binding domain; vaccine

Mesh：

Substances：

Year:  2020        PMID： 32991231      PMCID： PMC7993121          DOI： 10.1080/21645515.2020.1814098

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  8 in total

Review 1.  SARS vaccine development.

Authors:  Shibo Jiang; Yuxian He; Shuwen Liu
Journal:  Emerg Infect Dis       Date:  2005-07       Impact factor: 6.883

2.  Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.

Authors:  Jiaming Lan; Yanfeng Yao; Yao Deng; Hong Chen; Guangwen Lu; Wen Wang; Linlin Bao; Wei Deng; Qiang Wei; George F Gao; Chuan Qin; Wenjie Tan
Journal:  EBioMedicine       Date:  2015-08-18       Impact factor: 8.143

3.  Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus.

Authors:  Leon Chien-Wei Lin; Chen-Yu Huang; Bing-Yu Yao; Jung-Chen Lin; Anurodh Agrawal; Abdullah Algaissi; Bi-Hung Peng; Yu-Han Liu; Ping-Han Huang; Rong-Huay Juang; Yuan-Chih Chang; Chien-Te Tseng; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Adv Funct Mater       Date:  2019-04-12       Impact factor: 18.808

4.  The Challenges of Vaccine Development against a New Virus during a Pandemic.

Authors:  Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2020-05-13       Impact factor: 21.023

Review 5.  Fc-fusion proteins: new developments and future perspectives.

Authors:  Daniel M Czajkowsky; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  EMBO Mol Med       Date:  2012-07-26       Impact factor: 12.137

6.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.

Authors:  Xiuyuan Ou; Yan Liu; Xiaobo Lei; Pei Li; Dan Mi; Lili Ren; Li Guo; Ruixuan Guo; Ting Chen; Jiaxin Hu; Zichun Xiang; Zhixia Mu; Xing Chen; Jieyong Chen; Keping Hu; Qi Jin; Jianwei Wang; Zhaohui Qian
Journal:  Nat Commun       Date:  2020-03-27       Impact factor: 14.919

Review 7.  The SARS-CoV-2 Vaccine Pipeline: an Overview.

Authors:  Wen-Hsiang Chen; Ulrich Strych; Peter J Hotez; Maria Elena Bottazzi
Journal:  Curr Trop Med Rep       Date:  2020-03-03

8.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates.

Authors:  Qidi Wang; Lianfeng Zhang; Kazuhiko Kuwahara; Li Li; Zijie Liu; Taisheng Li; Hua Zhu; Jiangning Liu; Yanfeng Xu; Jing Xie; Hiroshi Morioka; Nobuo Sakaguchi; Chuan Qin; Gang Liu
Journal:  ACS Infect Dis       Date:  2016-04-11       Impact factor: 5.084
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.